Your browser is no longer supported. Please, upgrade your browser.
Nuvation Bio Inc.
Index- P/E- EPS (ttm)-0.44 Insider Own27.16% Shs Outstand207.10M Perf Week-8.00%
Market Cap2.04B Forward P/E- EPS next Y-0.63 Insider Trans-4.66% Shs Float119.20M Perf Month-2.18%
Income-125.30M PEG- EPS next Q-0.20 Inst Own69.60% Short Float7.77% Perf Quarter-2.82%
Sales- P/S- EPS this Y-91.30% Inst Trans2.18% Short Ratio12.44 Perf Half Y-32.35%
Book/sh3.71 P/B2.42 EPS next Y-38.60% ROA- Target Price18.20 Perf Year-10.66%
Cash/sh3.49 P/C2.57 EPS next 5Y- ROE- 52W Range7.30 - 15.23 Perf YTD-23.33%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-39.66% Beta-
Dividend %- Quick Ratio59.90 Sales past 5Y- Gross Margin- 52W Low25.89% ATR0.60
Employees58 Current Ratio59.90 Sales Q/Q- Oper. Margin- RSI (14)50.66 Volatility12.18% 6.70%
OptionableYes Debt/Eq0.00 EPS Q/Q-166.80% Profit Margin- Rel Volume0.75 Prev Close8.97
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume744.83K Price9.19
Recom1.50 SMA201.07% SMA50-2.02% SMA200-10.44% Volume341,094 Change2.45%
Oct-15-21Resumed BTIG Research Buy $16
Apr-06-21Initiated RBC Capital Mkts Outperform $15
Mar-08-21Initiated Wedbush Outperform $20
Mar-08-21Initiated Jefferies Buy $20
Mar-08-21Initiated Cowen Outperform
Mar-08-21Initiated BTIG Research Buy $16
Mar-08-21Initiated BMO Capital Markets Outperform $16
Nov-19-21 08:24AM  
Nov-10-21 04:05PM  
Oct-25-21 09:12AM  
Sep-20-21 04:14PM  
Aug-12-21 04:05PM  
Jul-06-21 10:20AM  
Jun-01-21 07:00AM  
May-26-21 07:00AM  
May-21-21 04:34PM  
May-17-21 05:00PM  
May-11-21 05:51AM  
Apr-17-21 09:36PM  
Mar-11-21 05:15PM  
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting CDK2, CDK4, and CDK6. It is also developing NUV-868, a selective inhibitor of the BET family of epigenetic transcriptional regulators; NUV-569, a differentiated selective inhibitor of the Wee1 kinase; NUV-1182, an adenosine receptor inhibitor; and DDC platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to androgen receptor-expressing cancer cells , as well as PARP inhibitor to ER-expressing cancer cells. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was incorporated in 2018 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
NODELMAN OLEGDirectorNov 24Buy7.69185,0261,422,0917,361,675Nov 30 06:07 PM
Omega Fund V, L.P.10% OwnerNov 23Sale9.753635124,857,376Nov 24 06:38 PM
Omega Fund V, L.P.10% OwnerNov 22Sale9.76295,0002,879,20024,857,376Nov 24 06:38 PM
Omega Fund V, L.P.10% OwnerNov 03Sale9.252,000,00018,500,00025,152,376Nov 05 05:31 PM
Omega Fund V, L.P.10% OwnerOct 29Sale9.2745,000417,15027,152,376Nov 01 05:01 PM
Omega Fund V, L.P.10% OwnerOct 28Sale9.601,015,0009,744,00027,197,376Nov 01 05:01 PM
NODELMAN OLEGDirectorJul 31Buy8.6456,598489,0077,198,407Nov 30 06:07 PM
NODELMAN OLEGDirectorJul 31Sale8.6456,598489,0071,147,483Nov 30 06:07 PM
NODELMAN OLEGDirectorApr 13Buy10.2731,500323,5376,990,265Apr 13 05:55 PM
NODELMAN OLEGDirectorApr 12Buy9.49133,0001,261,8776,962,731Apr 13 05:55 PM
NODELMAN OLEGDirectorApr 09Buy10.03300,0003,009,1806,846,476Apr 13 05:55 PM
NODELMAN OLEGDirectorMar 31Buy10.45151,5441,583,6356,735,790Nov 30 06:07 PM
Sharp ShaliniDirectorFeb 10Option Exercise0.0025,000025,000Feb 26 07:02 PM
BRADBURY DANIELDirectorFeb 10Option Exercise0.0025,000025,000Feb 26 07:01 PM
Hasnain FaheemDirectorFeb 10Option Exercise0.0025,000025,000Feb 26 07:00 PM
COOPER GRAHAM KDirectorFeb 10Option Exercise0.0025,000025,000Feb 26 06:59 PM